HYBRIGENICS : 2012 revenues and update on the clinical study of inecalcitol in chronic lymphocytic leukemia (CLL)

Press Release

Hybrigenics: 2012 revenues and update on the clinical study of inecalcitol in chronic lymphocytic leukemia (CLL)

Stable recurring revenues at EUR 4,9 million

Cash position strengthened at EUR 3.5 million

Enrolment on track for the Phase II clinical trial of inecalcitol in CLL

Paris, 31 January 2013 - Hybrigenics SA (ALHYG), a bio-pharmaceutical company listed on Alternext (NYSE-Euronext) in Paris, with a focus on research and development of new treatments against proliferative diseases and specialized in protein interaction services, today announces its revenues and cash position for the year ended December 31st, 2012 and gives an update on the enrolment status of the Phase II clinical study of oral inecalcitol in chronic lymphocytic leukemia (CLL) patients.

Million EUR 2012 2011 Growth
Recurring turnover from scientific activities 4.09 4.02 +2 % Other recurring operating revenues a 0.76 0.85 -11 % Non recurring operating revenue - 1.70b na

Non recurring exceptional revenue 0.96c - na

Total revenues 5.81 6.57 -12 % Cash Position (at year end) 3.54 2.70 +31 %

aresearch subsidies, subleases and services to subleasers; bupfront from the research collaboration contract with Servier; c exceptional income from the Ministry of Industry; na: not applicable.

In 2012, Hybrigenics' total recurring revenues were stable at EUR 4.85 million, the increase in turnover of scientific activities having compensated for the decrease in other recurring revenues. In 2012, an exceptional income of EUR 0.96 million from the Ministry of Industry has been booked (see Hybrigenics' press release of August 28, 2012) but, in 2011, a one-time EUR

1.7 million upfront payment had been triggered by the signature of a pharmaceutical research collaboration contract with Servier (see Hybrigenics' press release of October 10, 2011). This

EUR 0.74 million difference in non-recurring revenues fully accounts for the -12% decrease in total revenues. At the end of 2012, the cash position stood at EUR 3.5 million, 31% higher than at the end of 2011.

Update on the Phase II clinical study of inecalcitol in chronic lymphocytic leukemia

The Phase II clinical study is an open-label trial assessing the safety and potential efficacy of inecalcitol given to CLL patients not yet requiring immuno-chemotherapy but at high risk of disease progression. It is coordinated by Prof. Hermine, Head of Clinical Haematology at Necker Hospital in Paris, with the endorsement and active participation of the French Cooperative Group on CLL. The study was initially started in six centres in France; to enhance enrolment speed, seven additional centres have been opened.
1/3

Press Release

Inecalcitol is given orally at 2 milligrams per day during at least 6 months or until progression occurs. The objectives are to decrease or stabilize the number of blood-circulating CLL cells and to delay the onset of other signs of progression, such as swelling of lymph nodes or anemia and, thereby, the need for immuno-chemotherapy. Thirteen CLL patients are currently being treated with inecalcitol.
"The enrolment of CLL patients in the Phase II study of oral inecalcitol has gained momentum with the opening of new clinical centers which expressed an interest in participating to the study," said Jean-François Dufour-Lamartinie, Hybrigenics' Head of Clinical R&D. "In addition to the effective unfolding of the CLL trial, the steady performance of the scientific services in spite of a degraded general economic environment, and a careful cash management represent Hybrigenics' 2012 highlights" said Remi Delansorne, Hybrigenics' CEO.

About Chronic Lymphocytic Leukemia (CLL)

CLL is the most frequent form of leukemia (cancerous proliferative disease of circulating blood cells) and accounts for about 35% of all leukemic patients. Annual estimates of newly diagnosed CLL cases amount to close to 15,000 in the United States (American Leukemia Lymphoma Society, Facts 2012), 14,000 in

Europe and 130,000 world-wide (Globocan 2008). CLL is designated as an orphan disease in the United

States, Europe and Japan.

People with CLL produce too many lymphocytes (mononuclear white blood cells) of one single abnormal "family" (monoclonal) which are not fully developed (immature). Over time, these circulating CLL cells (monoclonal immature lymphocytes) in excess build up in the lymphatic system and cause large, swollen lymph nodes. They may also fill the bone marrow, reducing the number of normal white cells, red cells and platelets that can be made, thereby lowering their blood counts. There is no definitive cure for CLL.

About Hybrigenics

Hybrigenics (www.hybrigenics.com) is a bio-pharmaceutical company listed (ALHYG) on Alternext (NYSE- Euronext) in Paris, focusing its internal R&D programs on innovative targets and therapies for the treatment of proliferative cancerous or non-cancerous diseases.

Hybrigenics' current development program is based on inecalcitol, a vitamin D receptor agonist, for the first-line treatment of metastastic castrate-resistant prostate cancer in combination with Taxotere®, which is the current gold-standard chemotherapeutic treatment for this indication. Oral inecalcitol has been studied in a clinical trial for the treatment of moderate-to-severe psoriasis, and is currently being tested in chronic lymphocytic leukemia patients.

Hybrigenics has a research collaboration with Servier on deubiquitinating enzymes and their inhibitors in oncology, neurology, psychiatry, rheumatology, ophthalmology, diabetes and cardiovascular diseases.

Hybrigenics continues to build on its pioneer research position in the field of ubiquitin-specific proteases by exploring their role in other areas of particular relevance, such as inflammation and virology.

Hybrigenics Services SAS, a fully-owned subsidiary, is the market leader in Yeast Two-Hybrid (Y2H) and related services to identify, validate and inhibit protein interactions for researchers in all areas of life sciences, using its ISO 9001-certified high-throughput Y2H screening platform, its sophisticated bioinformatics tools and extensive database, along with its chemical library and chemical screening platform

2/3

Press Release

***
HYBRIGENICS is listed on the Alternext by NYSE Euronext Paris
ISIN: FR0004153930 - Ticker: ALHYG

Hybrigenics Rémi Delansorne CEO

Tel.: [phone] [e-mail]

NewCap.

Financial communication

Axelle Vuillermet / Pierre Laurent Tel.: [phone] [e-mail]

3/3